Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Sevenfact for hemophilia A and B

April 2, 2020

Step-1 primary endpoint met in phase III Atalante 1 trial of Tedopi in NSCLC

April 2, 2020

Accelerated by COVID-19, science changes will outlast pandemic

April 2, 2020

FORMA Therapeutics identifies new pyruvate kinase PKLR activators

April 2, 2020

New RIP-1 inhibitors identified at Bristol-Myers Squibb

April 2, 2020

Primmune selects PRTX-007 for development for SARS-CoV-2 prophylaxis

April 2, 2020

Yale University, Arvinas Operations disclose new PROTAC compounds

April 2, 2020

Novel series of sulfamoylbenzamides modulating capsid assembly to target hepatitis B virus infection

April 2, 2020

Ohio State University patents lipid nanoparticles modulating Bcl-2, Akt-1

April 2, 2020

New potent and selective ATP-competitive mTOR inhibitor with brain penetrance for CNS disorders

April 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.